Eli Lilly’s Weight-Loss Treatment Found To Help Those With Sleep Apnea

Related Articles

This Event Could Be the Next Catalyst for Intel’s Stock

S&P 500 Gains and Losses Today: Charter Communications Soars as Subscriber Growth Impresses

Nintendo Switch 2 Pre-Orders Are Hot Tickets After Tariff Delay

Key Takeaways

• Eli Lilly on Wednesday said its weight-loss treatment, Zepbound, was successful in helping patients with obstructive rest apnea (OSA).
• A Phase 3 trial found on average Zepbound reduced the number of sleep-apnea events by up to 63%.
• The drug maker outlines to ask the Food and Drug Administration (FDA) and other regulators to expand the use of Zepbound for OSA by mid-year.

Shares of Eli Lilly (LLY) gained in intraday shopper Wednesday after the pharmaceutical firm said a late-stage study found its weight-loss drug, Zepbound, was effective in healing those who are overweight and suffer from obstructive sleep apnea (OSA).

The company said that in a Phase 3 trial, on usual, Zepbound reduced by up to 63% the apnea-hypopnea index (AHI) in the test group, achieving all primary and key secondary endpoints. AHI records the multitude of times a person’s breathing shows a restricted or complete block of airflow per hour of sleep, and is used to measure the abusiveness of OSA. Lilly pointed out that at the top end of the findings, use of Zepbound cut the number of events by 30 an hour. 

Dr. Jeff Emmick, senior profligacy president of development at Lilly, explained that OSA affects 80 million adults in the U.S., with more than 20 million be suffering with moderate or severe cases. He added that while other drugs for excessive sleeplessness associated with OSA now endure, Zepbound “has the potential to be the first pharmaceutical treatment for the underlying disease.”

Lilly noted that based on these emerges, it plans to submit authorization requests for expanded use of Zepbound for OSA to the Food and Drug Administration (FDA) and other global regulatory associations beginning in the middle of the year. 

Zepbound is sold as Mounjaro in some global markets outside the U.S.

Eli Lilly shares be generate 0.5% to $750.30 each as of noon ET Wednesday and have added almost 27% so far this year. The news sent share outs of ResMed (RMD), which makes devices to treat sleep apnea, down 6% to $173.39.

Read the original article on Investopedia.